E VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers

(Click on image to enlarge)

Although it may seem daunting to buy in after the recent ramp up, the rise comes on real substantiated news based on their successful capital raise and progress dealing with social anxiety which there isn’t an adequate drug on the market for. It doesn’t factor in final approval of their drugs and the fact that their enhanced financial clout will enable it to broaden their horizons in rapidly developing a market and pursuing other growth prospects in this market segment.

Like with PH94B, PH10 has a strong argument for approval and there is a desperate need for rapid-acting and effective treatments for Major Depressive Disorder. 

Last AV-101 in Combination with Probenecid is compelling in its own right with its potential for dealing with a variety of depression disorders.

As many know, I tend to get excited at pharmaceutical companies that have multiple chances at success and have the ability to grow beyond a single success and become a leader in a field. I believe that VistaGen meets both criteria and although it comes at a premium, the good news is the table is already set and the banquet is just starting.

Ever Insight/CBC Group are championing them in Asia. OrbiMed, Venrock Healthcare Capital Partners, Acuta Capital, New Enterprise Associates, and others were involved in the recent offering and will likely be around to support the company as it grows. I believe this is just the start for this company and it is more than ready to garner new partners and institutional investors in 2021. It is a good company that is delivering on its promises with a slate of very promising drugs. As one says about good investments, what’s not to like.

1 2
View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Moon Kil Woong 4 months ago Author's comment

Here are some article to help look at the news in perspective:


Bill Johnson 6 months ago Member's comment

Sounds impressive to me.

Moon Kil Woong 6 months ago Author's comment

Thanks, I agree there are good prospects for this company and the price will likely continue to rise.

Terrence Howard 6 months ago Member's comment

Good article, thanks. Totally unrelated but what do you think about $AZN? I know Pfizer and Moderna have the head start on the vaccine, but it sounds like AZN's drug will be almost as effective at 90% efficacy (if they can replicate their initial test where they accidentally gave a quarter of the participants a 1/2 dose). And at $2 per vial instead of $200, I would think it will be the drug of choice for populous, yet poor nations like India, and Africa. Plus there will be no need for specialized freezers.

Moon Kil Woong 6 months ago Author's comment

I'm not that big on the vaccines. As you know they mutate and they all get around 80-90% effectiveness. I'd play drugs that cure or help the infected. I wrote on one of them but there are also others. The vaccine effort was most heavily pushed by the Trump administration and people played it for the free money given out for development mostly.

That said, not using freezers is a big benefit. In Africa the spike has already changed so it is clear that Covid can change its spike potentially evading modern vaccines like the flu. This would be my biggest concern about the viability of vaccines.

Terrence Howard 6 months ago Member's comment

Thanks for your thoughts. Makes a lot of sense.

Stock Fan 6 months ago Member's comment

Great read. The price is low enough I picked up a few shares.

Moon Kil Woong 6 months ago Author's comment

It's great to hear from you. I'm glad you enjoyed it.

Beating Buffett 6 months ago Member's comment

Good stuff.